Ligands that target cannabinoid receptors in the brain: From THC to anandamide and beyond

Addiction Biology

Volumn 13, Issue 2, 2008, Pages 147-159

  Pertwee, Roger G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

9 tetrahydrocannabinol; Anandamide; Cannabinoid receptors; Cannabis; Clinical applications of cannabinoids; Endocannabinoid system

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CHOLECYSTOKININ; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; CYTOKINE; DEXANABINOL; DEXTRO ASPARTIC ACID; DOPAMINE; DRONABINOL; ENDOCANNABINOID; GLUTAMIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; METHANANDAMIDE; NABILONE; NORADRENALIN; PALMITYLSULFONYL FLUORIDE; SEROTONIN; UNINDEXED DRUG;

BRAIN REGION; CANNABIS ADDICTION; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; DRUG INHIBITION; GENETIC TRANSFECTION; HOMEOSTASIS; HUMAN; HYDROLYSIS; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW;

ANIMALS; ARACHIDONIC ACIDS; BRAIN; CANNABINOIDS; ENDOCANNABINOIDS; GLYCERIDES; HUMANS; MARIJUANA ABUSE; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TETRAHYDROCANNABINOL;

EID: 43949121784     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2008.00108.x     Document Type: Review

References (133)

1. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, Mackie K, Marian C, Batkai S, Parolaro D, Fischer MJ, Reeh P, Kunos G, Kress M, Lutz B, Woolf CJ, Kuner R (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10 : 870 879.
2. Alexander JP, Cravatt BF (2006) The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J Am Chem Soc 128 : 9699 9704.
3. Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S, Reggiani A (2006) CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 23 : 1530 1538.
4. Bisogno T, Cascio MG, Saha B, Mahadevan A, Urbani P, Minassi A, Appendino G, Saturnino C, Martin B, Razdan R, Di Marzo V (2006) Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 1761 : 205 212.
5. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams E-J, Gangadharan U, Hobbs C, Di Marzo V, Doherty P (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163 : 463 468.
6. Boström J, Berggren K, Elebring T, Greasley PJ, Wilstermann M (2007) Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists. Bioorg Med Chem 15 : 4077 4084.
7. 2 phosphorylation by the inverse agonist SR 144528: implications for receptor biological responses. J Biol Chem 274 : 20397 20405.
8. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, Maffrand J-P, Le Fur G, Casellas P (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272 : 22330 22339.
9. 9- Tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. Eur J Pharmacol 506 : 63 69.
10. Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim Selley LJ (1999) Chronic Δ9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 73 : 2447 2459.
11. Cabral GA, Staab A (2005) Effects on the immune system. In : Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168, pp. 385 423. Heidelberg : Springer-Verlag.
12. Calandra B, Portier M, Kernéis A, Delpech M, Carillon C, Le Fur G, Ferrara P, Shire D (1999) Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor. Eur J Pharmacol 374 : 445 455.
13. 2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology 38 : 533 541.
14. Chen C, Frey LF, Shultz S, Wallace DJ, Marcantonio K, Payack JF, Vazquez E, Springfield SA, Zhou G, Liu P, Kieczykowski GR, Chen AM, Phenix BD, Singh U, Strine J, Izzo B, Krska SW (2007) Catalytic, enantioselective synthesis of taranabant, a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. Org Process Res Dev 11 : 616 623.
15. Childers SR (2006) Activation of G-proteins in brain by endogenous and exogenous cannabinoids. AAPS J 8 : E112 E117.
16. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98 : 9371 9376.
17. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 : 83 87.
18. Cravatt BF, Lichtman AH (2004) The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 61 : 149 160.
19. De Petrocellis L, Melck D, Ueda N, Maurelli S, Kurahashi Y, Yamamoto S, Marino G, Di Marzo V (1997) Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase. Biochem Biophys Res Commun 231 : 82 88.
20. 1 receptors and endovanilloids. Exp Cell Res 313 : 1911 1920.
21. Després J-P, Lemieux I, Alméras N (2006) Contribution of CB1 blockade to the management of high-risk abdominal obesity. Int J Obes 30 : S44 S52.
22. Deutsch DG, Lin S, Hill WAG, Morse KL, Salehani D, Arreaza G, Omeir RL, Makriyannis A (1997a) Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem Biophys Res Commun 231 : 217 221.
23. Deutsch DG, Omeir R, Arreaza G, Salehani D, Prestwich GD, Huang Z, Howlett A (1997b) Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem Pharmacol 53 : 255 260.
24. Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 : 1946 1949.
25. De Vry J, Jentzsch KR, Kuhl E, Eckel G (2004) Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol 15 : 1 12.
26. Di Marzo V, Bisogno T, De Petrocellis L, Brandi I, Jefferson RG, Winckler RL, Davis JB, Dasse O, Mahadevan A, Razdan RK, Martin BR (2001) Highly selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor 'hybrid' ligands. Biochem Biophys Res Commun 281 : 444 451.
27. Di Marzo V, De Petrocellis L, Bisogno T (2005) The biosynthesis, fate and pharmacological properties of endocannabinoids. In : Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168, pp. 147 185. Heidelberg : Springer-Verlag.
28. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99 : 10819 10824.
29. Fernández-Ruiz J, González S (2005) Cannabinoid control of motor function at the basal ganglia. In : Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168, pp. 479 507. Heidelberg : Springer-Verlag.
30. Fox A, Bevan S (2005) Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert Opin Investig Drugs 14 : 695 703.
31. Gardner EL (2005) Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 81 : 263 284.
32. Giblin GMP, O'Shaughnessy CT, Naylor A, Mitchell WL, Eatherton AJ, Slingsby BP, Rawlings DA, Goldsmith P, Brown AJ, Haslam CP, Clayton NM, Wilson AW, Chessell IP, Wittington AR, Green R (2007) Discovery of 2-[(2,4- dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl) methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J Med Chem 50 : 2597 2600.
33. Glass M, Felder CC (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17 : 5327 5333.
34. Gong J-P, Onaivi ES, Ishiguro H, Liu Q-R, Tagliaferro PA, Brusco A, Uhl GR (2006) Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071 : 10 23.
35. Guzmán M (2005) Effects on cell viability. In : Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168, pp. 627 642. Heidelberg : Springer-Verlag.
36. Haller J, Mátyás F, Soproni K, Varga B, Barsy B, Németh B, Mikics É, Freund TF, Hájos N (2007) Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur J Neurosci 25 : 2445 2456.
37. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87 : 1932 1936.
38. Hillard CJ, Jarrahian A (2003) Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol 140 : 802 808.
39. Ho S-Y, Delgado L, Storch J (2002) Monoacylglycerol metabolism in human intestinal Caco-2 cells: evidence for metabolic compartmentation and hydrolysis. J Biol Chem 277 : 1816 1823.
40. Ho W-SV, Hillard CJ (2005) Modulators of endocannabinoid enzymic hydrolysis and membrane transport. In : Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168, pp. 187 207. Heidelberg : Springer-Verlag.
41. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435 : 1108 1112.
42. Howlett AC (2005) Cannabinoid receptor signaling. In : Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168, pp. 53 79. Heidelberg : Springer-Verlag.
43. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54 : 161 202.
44. Idris AI, Van't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH (2005) Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 11 : 774 779.
45. Izzo AA, Coutts AA (2005) Cannabinoids and the digestive tract. In : Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168, pp. 573 598. Heidelberg : Springer-Verlag.
46. 1 cannabinoid receptor. J Pharmacol Exp Ther 308 : 880 886.
47. Jin KL, Mao XO, Goldsmith PC, Greenberg DA (2000) CB1 cannabinoid receptor induction in experimental stroke. Ann Neurol 48 : 257 261.
48. Justinova Z, Goldberg SR, Heishman SJ, Tanda G (2005) Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol Biochem Behav 81 : 285 299.
49. Kaczocha M, Hermann A, Glaser ST, Bojesen IN, Deutsch DG (2006) Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase. J Biol Chem 281 : 9066 9075.
50. Karlsson M, Reue K, Xia Y-R, Lusis AJ, Langin D, Tornqvist H, Holm C (2001) Exon-intron organization and chromosomal localization of the mouse monoglyceride lipase gene. Gene 272 : 11 18.
51. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9 : 76 81.
52. 9-tetrahydrocannabinol antagonizes endocannabinoid modulation of synaptic transmission between hippocampal neurons in culture. Neuropharmacology 46 : 709 715.
53. Kim K, Moore DH, Makriyannis A, Abood ME (2006) AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol 542 : 100 105.
54. Kirkham TC, Williams CM (2001) Endogenous cannabinoids and appetite. Nutr Res Rev 14 : 65 86.
55. Kreitzer AC (2005) Neurotransmission: emerging roles of endocannabinoids. Curr Biol 15 : R549 R551.
56. Lang W, Qin C, Hill WAG, Lin S, Khanolkar AD, Makriyannis A (1996) High-performance liquid chromatographic determination of anandamide amidase activity in rat brain microsomes. Anal Biochem 238 : 40 45.
57. 1 cannabinoid receptor antagonists. Drug Discov Today 10 : 693 702.
58. 1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 312 : 875 883.
59. Leung D, Saghatelian A, Simon GM, Cravatt BF (2006) Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45 : 4720 4726.
60. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, Cravatt BF (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311 : 441 448.
61. Lichtman AH, Martin BR (2005) Cannabinoid tolerance and dependence. In : Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168, pp. 691 717. Heidelberg : Springer-Verlag.
62. Lim G, Sung B, Ji R-R, Mao J (2003) Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 105 : 275 283.
63. Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT, Gonsiorek W, Schwarz MA, Lavey B, Kozlowski JA, Narula SK, Lundell DJ, Hipkin RW, Bober LA (2006) A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther 316 : 780 788.
64. Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. In : Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168, pp. 299 325. Heidelberg : Springer-Verlag.
65. Mallat A, Teixeira-Clerc F, Deveaux V, Lotersztajn S (2007) Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opin Ther Targets 11 : 403 409.
66. Maneuf YP, Brotchie JM (1997) Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol 120 : 1397 1398.
67. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN (2005) Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95 : 437 445.
68. Martin BR, Beletskaya I, Patrick G, Jefferson R, Winckler R, Deutsch DG, Di Marzo V, Dasse O, Mahadevan A, Razdan RK (2000) Cannabinoid properties of methylfluorophosphonate analogs. J Pharmacol Exp Ther 294 : 1209 1218.
69. Massi P, Patrini G, Rubino T, Fuzio D, Parolaro D (1997) Changes in rat spleen cannabinoid receptors after chronic CP-55,940: an autoradiographic study. Pharmacol Biochem Behav 58 : 73 78.
70. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 : 561 564.
71. Mechoulam R (1986) The pharmacohistory of Cannabis sativa. In : Mechoulam R, ed. Cannabinoids as Therapeutic Agents, pp. 1 19. Boca Raton : CRC Press.
72. Mechoulam R, Ben-Shabat S, Hanuš L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50 : 83 90.
73. Mitrirattanakul S, Ramakul N, Guerrero AV, Matsuka Y, Ono T, Iwase H, Mackie K, Faull KF, Spigelman I (2006) Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 126 : 102 114.
74. Monory K, Massa F, Egertová M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein JL, Goebbels S, Nave K-A, During M, Klugmann M, Wölfel B, Dodt H-U, Zieglgänsberger W, Wotjak CT, Mackie K, Elphick MR, Marsicano G, Lutz B (2006) The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51 : 455 466.
75. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 : 61 65.
76. 9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice. Pharmacol Biochem Behav 84 : 330 336.
77. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I (2006) Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA 103 : 696 701.
78. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279 : 5298 5305.
79. O'Sullivan SE, Tarling EJ, Bennett AJ, Kendall DA, Randall MD (2005) Novel time-dependent vascular actions of Δ9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem Biophys Res Commun 337 : 824 831.
80. Oz M (2006) Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. Pharmacol Ther 111 : 114 144.
81. Pacher P, Bátkai S, Kunos G (2005) Cardiovascular pharmacology of cannabinoids. In : Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168, pp. 599 625. Heidelberg : Springer-Verlag.
82. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol Pharmacol 54 : 1064 1072.
83. Parker LA, Limebeer C, Kwiatkowska L, M (2005) Cannabinoids: effects on vomiting and nausea in animal models. In : Mechoulam R, ed. Cannabinoids as Therapeutics, pp. 183 200. Birkhaüser Verlag : Basel.
84. Pertwee R (1993) The evidence for the existence of cannabinoid receptors. Gen Pharmacol 24 : 811 824.
85. Pertwee RG (1988) The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 36 : 189 261.
86. 2 receptors. Pharmacol Ther 74 : 129 180.
87. Pertwee RG (1999) Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6 : 635 664.
88. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63 : 569 611.
89. Pertwee RG (2004) Novel pharmacological targets for cannabinoids. Curr Neuropharmacol 2 : 9 29.
90. Pertwee RG (2005a) Pharmacological actions of cannabinoids. In : Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168, pp. 1 51. Heidelberg : Springer-Verlag.
91. 1 receptors. Life Sci 76 : 1307 1324.
92. Pertwee RG (2005c) The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 7 : E625 E654.
93. Pertwee RG (2006) Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147 : S163 S171.
94. Pertwee RG (2007a) Cannabinoids and multiple sclerosis. Mol Neurobiol 36 : 45 59.
95. Pertwee RG (2007b) GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol 152 : 984 986.
96. Pertwee RG, Ross RA (2002) Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66 : 101 121.
97. 8- and Δ9-tetrahydrocannabivarin in mice in vivo. Br J Pharmacol 150 : 586 594.
98. 1 dopamine receptors. Neuropharmacology 50 : 661 670.
99. 9-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 948 : 155 158.
100. 1 receptor. Mol Pharmacol 68 : 1484 1495.
101. Raman C, McAllister SD, Rizvi G, Patel SG, Moore DH, Abood ME (2004) Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord 5 : 33 39.
102. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Soubrié P, Brelière JC, Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350 : 240 244.
103. Rinaldi-Carmona M, Barth F, Millan J, Derocq J-M, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Brelière J-C, Le Fur G (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284 : 644 650.
104. Robson P (2005) Human studies of cannabinoids and medicinal cannabis. In : Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168, pp. 719 756. Heidelberg : Springer-Verlag.
105. 2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 126 : 665 672.
106. Ross RA, Coutts AA, McFarlane SM, Anavi-Goffer S, Irving AJ, Pertwee RG, MacEwan DJ, Scott RH (2001) Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 40 : 221 232.
107. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson N-O, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152 : 1092 1101.
108. Savinainen JR, Järvinen T, Laine K, Laitinen JT (2001) Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB1 receptor-dependent G-protein activation in rat cerebellar membranes. Br J Pharmacol 134 : 664 672.
109. Savinainen JR, Kokkola T, Salo OMH, Poso A, Järvinen T, Laitinen JT (2005) Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor. Br J Pharmacol 145 : 636 645.
110. 1 and cannabinoid CB1 receptors. Br J Pharmacol 140 : 1451 1459.
111. Shen M, Thayer SA (1999 9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol 55 : 8 13.
112. Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL (2007) The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 101 : 87 98.
113. Siegling A, Hofmann HA, Denzer D, Mauler F, De Vry J (2001) Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 415 : R5 R7.
114. 35S]GTPγS autoradiography in rat brain. J Neurosci 16 : 8057 8066.
115. Sim-Selley LJ (2003) Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15 : 91 119.
116. 9-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther 303 : 36 44.
117. Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facci L, Leon A (1996) The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA 93 : 3984 3989.
118. Straiker A, Mackie K (2005) Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J Physiol 569 : 501 517.
119. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K (1995) 2-arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215 : 89 97.
120. Szabo B, Schlicker E (2005) Effects of cannabinoids on neurotransmission. In : Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168, pp. 327 365. Heidelberg : Springer-Verlag.
121. Thomas A, Pertwee RG (2006) The bioassay of cannabinoids using the mouse isolated vas deferens. In : Onaivi ES, ed. Marijuana and Cannabinoid Research. pp. 191 207. Totowa, NJ : Humana Press.
122. Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, Pertwee RG (2005) Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146 : 917 926.
123. Tomida I, Pertwee RG, Azuara-Blanco A (2004) Cannabinoids and glaucoma. Br J Ophthalmol 88 : 708 713.
124. Tramer MR, Carroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323 : 16 21.
125. Valverde O, Karsak M, Zimmer A (2005) Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. In : Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168, pp. 117 145. Heidelberg : Springer-Verlag.
126. Vandevoorde S, Jonsson K-O, Labar G, Persson E, Lambert DM, Fowler CJ (2007) Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro. Br J Pharmacol 150 : 186 191.
127. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 : 329 332.
128. Vaughan CW, Christie MJ (2005) Retrograde signalling by endocannabinoids. In : Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168, pp. 367 383. Heidelberg : Springer-Verlag.
129. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P (2006) Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes. J Neurosci Res 83 : 1310 1322.
130. Walker JM, Hohmann AG (2005) Cannabinoid mechanisms of pain suppression. In : Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168, pp. 509 554. Heidelberg : Springer-Verlag.
131. Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ (2003) The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 307 : 129 137.
132. Wotherspoon G, Fox A, McIntyre P, Colley S, Bevan S, Winter J (2005) Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135 : 235 245.
133. Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D (2003) Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17 : 2750 2754.